🚀 VC round data is live in beta, check it out!
Largest BioTech Public Companies in the US
Benchmark revenue and EBITDA valuation multiples for public comps like
Eli Lilly, Johnson & Johnson, AbbVie, Merck and Thermo Fisher Scientific.
 | $927 | +3% | $828B | $863B | 12.3x | 26.4x | ||
| $234 | +50% | $564B | $592B | 6.2x | 16.5x | ||
| $208 | +7% | $369B | $431B | 6.8x | 16.2x | ||
| $119 | +40% | $294B | $329B | 5.0x | 12.0x | ||
| $527 | +23% | $196B | $225B | 5.0x | 19.8x | ||
| $355 | +22% | $192B | $237B | 6.4x | 12.7x | ||
| $138 | +29% | $171B | $186B | 6.3x | 11.8x | ||
| $28 | +13% | $157B | $207B | 3.3x | 8.8x | ||
| $195 | -2% | $138B | $153B | 6.1x | 19.5x | ||
| $60 | +20% | $123B | $159B | 3.3x | 9.2x | ||
| $441 | -13% | $112B | $108B | 8.8x | 19.9x | ||
| $751 | +25% | $79B | $73B | 5.0x | 14.0x | ||
| $839 | +30% | $52B | $48B | 10.0x | 34.1x | ||
| Pet Care+1 | $122 | -22% | $51B | $58B | 6.1x | 13.9x | |
| $589 | +36% | $47B | $48B | 10.8x | 30.6x | ||
| $310 | +18% | $41B | $40B | 9.3x | 47.1x | ||
| $26 | +20% | $37B | $34B | 5.9x | 46.3x | ||
| $122 | +13% | $34B | $36B | 5.1x | 17.4x | ||
| $75 | +6% | $34B | $40B | 1.9x | 10.7x | ||
| $22 | -15% | $33B | $32B | 5.8x | 14.9x | ||
| $328 | -6% | $32B | $33B | 8.0x | 23.8x | ||
| $145 | +101% | $31B | $30B | 32.5x | (29.9x) | ||
| $149 | +268% | $31B | $29B | 1829.8x | (22.3x) | ||
| $176 | +14% | $30B | $43B | 2.6x | 11.3x | ||
| $208 | +38% | $30B | $29B | 11.9x | (110.2x) | ||
| $1,341 | +25% | $27B | $29B | 7.2x | 22.9x | ||
| $177 | +46% | $26B | $29B | 2.9x | 9.3x | ||
| $103 | -1% | $26B | $9B | 2.8x | (7.1x) | ||
| $588 | +94% | $26B | $23B | 7.0x | 13.3x | ||
| $271 | +12% | $22B | $28B | 2.0x | 11.6x | ||
| $50 | +52% | $22B | $30B | 9.0x | 9.8x | ||
| $195 | +9% | $22B | $28B | 2.5x | 12.4x | ||
| $54 | +88% | $21B | $17B | 8.5x | (5.9x) | ||
| $215 | -10% | $21B | $23B | 6.5x | 21.2x | ||
| $134 | +73% | $20B | $21B | 4.9x | 17.2x | ||
| $104 | +127% | $20B | $21B | — | — | ||
| $25 | +4% | $20B | $19B | 8201.3x | (19.4x) | ||
| $98 | +56% | $19B | $16B | 3.0x | 9.8x | ||
| $113 | +44% | $17B | $19B | 2.6x | 6.1x | ||
| $15 | +74% | $17B | $30B | 2.1x | 7.2x | ||
| $76 | +30% | $17B | $17B | — | — | ||
| $66 | +57% | $16B | $15B | 45.2x | (451.3x) | ||
| $77 | +100% | $15B | $16B | 25.9x | (36.6x) | ||
| $520 | +69% | $15B | $14B | 5.5x | 25.2x | ||
| $204 | -19% | $14B | $14B | 5.0x | 21.0x | ||
| $70 | -14% | $14B | $16B | 3.8x | 12.1x | ||
| $133 | +24% | $13B | $12B | 4.1x | 16.8x | ||
| $332 | +13% | $13B | $13B | 8.7x | 45.2x | ||
| $203 | +74% | $13B | $16B | 3.6x | 14.2x | ||
| $76 | +147% | $13B | $12B | 13.1x | (28.2x) | ||
| $532 | +59% | $12B | $12B | 10.4x | — | ||
| $90 | +91% | $12B | $12B | 11.6x | (59.1x) | ||
| $24 | +150% | $12B | $15B | 3.2x | 16.6x | ||
| $45 | +15% | $11B | $11B | 4.4x | 10.4x | ||
| $55 | -14% | $11B | $10B | 2.9x | 13.6x | ||
| $94 | +1% | $11B | $13B | 4.5x | 15.0x | ||
| $70 | +400% | $10B | $9B | 14.6x | (87.1x) | ||
| $189 | +68% | $10B | $10B | 13.0x | (75.9x) | ||
| $19 | -40% | $10B | $17B | 1.5x | 8.0x | ||
| $342 | +819% | $10B | $9B | 5072.0x | (25.0x) | ||
| $59 | +18% | $9B | $9B | 7.7x | 21.7x | ||
| $120 | -21% | $9B | $12B | 1.5x | 8.0x | ||
| $184 | +55% | $9B | $11B | 2.9x | 11.8x | ||
| $62 | +74% | $9B | $8B | — | (7.7x) | ||
| $41 | -8% | $8B | $9B | 4.3x | 11.9x | ||
| $108 | +40% | $8B | $7B | 1736.4x | (17.3x) | ||
| $67 | +56% | $8B | $9B | 96.7x | (13.3x) | ||
| $69 | +13% | $8B | $10B | 6.8x | 12.6x | ||
| $274 | +61% | $8B | $7B | 16.9x | 40.0x | ||
| $8 | +206% | $8B | $8B | 57.9x | — | ||
| $131 | -5% | $7B | $7B | 9.6x | 49.4x | ||
| $125 | +32% | $7B | $7B | 13.2x | (401.9x) | ||
| $115 | -13% | $7B | $8B | 1.1x | 6.6x | ||
| $88 | +156% | $7B | $6B | 162.5x | (18.8x) | ||
| $92 | +135% | $7B | $6B | — | (20.1x) | ||
| $106 | +131% | $7B | $6B | 38.1x | (269.6x) | ||
| $115 | +77% | $7B | $6B | 151.8x | (25.9x) | ||
| $166 | +169% | $7B | $6B | 805.1x | (67.7x) | ||
| $73 | +379% | $6B | $6B | — | (25.8x) | ||
| $73 | +173% | $6B | $5B | 772.0x | (26.8x) | ||
| $53 | +1495% | $6B | $5B | — | (43.6x) | ||
| $89 | +36% | $6B | $6B | 26.1x | (29.8x) | ||
| $37 | +615% | $6B | $5B | 1038.4x | (17.3x) | ||
| $72 | +182% | $6B | $6B | 1486.0x | (367.6x) | ||
| $72 | +45% | $6B | $7B | 4.5x | 10.0x | ||
| $29 | +82% | $6B | $5B | — | (10.7x) | ||
| $634 | +3% | $6B | $7B | 2.5x | — | ||
| $122 | +999% | $6B | $6B | 345.5x | (31.0x) | ||
| $98 | +125% | $6B | $6B | 10.5x | (231.8x) | ||
| $19 | +1202% | $6B | $6B | — | (37.1x) | ||
| $35 | +20% | $6B | $5B | 3.3x | 13.3x | ||
| $50 | +52% | $6B | $5B | 1052.0x | (14.4x) | ||
| $177 | +13% | $6B | $6B | 5.5x | 20.6x | ||
| $35 | -22% | $6B | $6B | 8.2x | 35.5x | ||
| $41 | +113% | $5B | $5B | 5.4x | 427.9x | ||
| $93 | +327% | $5B | $5B | 2502.5x | — | ||
| $46 | -36% | $5B | $5B | 5.7x | 34.1x | ||
| $16 | +42% | $5B | $7B | 5.5x | 10.9x | ||
| $232 | +111% | $5B | $4B | 16.2x | 35.0x | ||
| $14 | +88% | $5B | $5B | 7.0x | 30.5x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.